Pharmacovigilance risk signals have proposed a relationship between the use of acid-suppressive medications and the development of certain autoimmune and immune-mediated inflammatory diseases.
OBJECTIVE:
A systematic review and a meta-analysis was performed.
METHODS:
We reviewed MEDLINE (Ovid) and Scopus for comparative observational studies between these diseases and previous exposure to proton-pump inhibitors (PPI), H2-receptor antagonists (H2RA), and antacids. The protocol was registered on the PROSPERO database (CRD42020192715).
RESULTS:
From 3,191 citations, 25 articles were eligible and covered 16 diseases. Microscopic colitis (MC) was studied the most (7 studies). In a random-effects meta-analysis, there was low certainty evidence (GRADE approach) of a non-significant relationship between exposure to any PPIs and MC (meta-OR 3.28, 95% CI 0.98–11.0, I2 98.2%, six studies, 4,436 PPI-exposed MC patients). Moderate certainty evidence pointed towards large odds of collagenous colitis after exposure to lansoprazole (meta-OR 14.5, 95% CI 9.37–22.3, I2 10.2%, three studies, 1,725 lansoprazole-exposed patients). After PPI exposure, the risk of rheumatoid arthritis was slightly increased based on low certainty evidence from two cohort studies totaling 475 diagnoses (meta-RR 1.62, 95% CI 1.12–2.34, I2 34.5%).
CONCLUSIONS:
In patients with MC, it would be reasonable to carefully review the indication of PPI, especially in CC patients using lansoprazole.
BeaugerieLPardiDS. Review article: Drug-induced microscopic colitis – proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005;22(4):277–84. doi:10.1111/j.1365-2036.2005.02561.x.
2.
AggarwalN. Drug-induced subacute cutaneous lupus erythematosus associated with proton pump inhibitors. Drugs – Real World Outcomes. 2016;3(2):145–54. doi:10.1007/s40801-016-0067-4.
SaferDJ. Overprescribed medications for US adults: Four major examples. J Clin Med Res. 2019;11(9):617–22. doi:10.14740/jocmr3906.
5.
XiaoXChangC. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun. 2014;48–49:66–72. doi:10.1016/j.jaut.2014.01.005.
6.
Manfredo VieiraSHiltenspergerMKumarVTranslocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018;359(6380):1156–61. doi:10.1126/science.aar7201.
7.
ImhannFBonderMJVich VilaAProton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8. doi:10.1136/gutjnl-2015-310376.
8.
JacksonMAGoodrichJKMaxanMProton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56. doi:10.1136/gutjnl-2015-310861.
9.
LewisSJFrancoSYoungGAltered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557–61. doi:10.1046/j.1365-2036.1996.d01-506.x.
10.
TakashimaSTanakaFKawaguchiYProton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice. Neurogastroenterol Motil. 2020;32(7):e13841. doi:10.1111/nmo.13841.
11.
BurgelNBojarskiCMankertzJMechanisms of diarrhea in collagenous colitis. Gastroenterology. 2002;123(2):433–43. doi:10.1053/gast.2002.34784.
12.
PageMJMcKenzieJEBossuytPMThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
13.
WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2021. Oslo, Norway 2020. Available from: https://www.whocc.no/atc_ddd_index/.
14.
WellsGSBO’ConnellDPetersonJWelchVLososMThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.3rd Symposium on Systematic Reviews: Beyond the Basics.2000.
15.
BalshemHHelfandMSchunemannHJGRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–6. doi:10.1016/j.jclinepi.2010.07.015.
16.
RStudio Team. RStudio: Integrated development environment for R. RStudio, PBC, Boston, MA; 2020. Available from: http://www.rstudio.com/. Accessed April 17, 2021.
17.
ViechtbauerW. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software. 2010;36(3):1–48. doi:10.18637/jss.v036.i03.
18.
HigginsJPThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;15;21(11):1539–58. doi:10.1002/sim.1186.
19.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane; 2020. Available from: www.training.cochrane.org/handbook. Accessed April 17, 2021.
20.
BlomgrenKBSundströmASteineckGA Swedish case-control network for studies of drug-induced morbidity–acute pancreatitis. Eur J Clin Pharmacol. 2002;58(4):275–83. doi:10.1007/s00228-002-0471-4.
21.
BonderupOKFenger-GronMWighTDrug exposure and risk of microscopic colitis: A nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis. 2014;20(10):1702–7. doi:10.1097/MIB.0000000000000143.
22.
BonderupOKNielsenGLDallMSignificant association between the use of different proton pump inhibitors and microscopic colitis: A nationwide Danish case-control study. Aliment Pharmacol Ther. 2018;48(6):618–25. doi:10.1111/apt.14916.
23.
ChenHLinJYangBRisk of systemic autoimmune diseases in gastric disease patients with proton pump inhibitor use: A nationwide cohort study in Taiwan. Clin Rheumatol. 2020;39(9):2773–80. doi:10.1007/s10067-020-05012-8.
24.
CorpechotCChrétienYChazouillèresODemographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53(1):162–9. doi:10.1016/j.jhep.2010.02.019.
25.
DourosABronderEAndersohnFDrug-induced acute pancreatitis: Results from the hospital-based Berlin case-control surveillance study of 102 cases. Aliment Pharmacol Ther. 2013;38(7):825–34. doi:10.1111/apt.12461.
26.
ElandIAAlvarezCHStrickerBHThe risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol. 2000;49(5):473–8. doi:10.1046/j.1365-2125.2000.00196.x.
27.
EvansJMMcMahonADSteinkeDTDo H2-receptor antagonists cause acute pancreatitis?Pharmacoepidemiol Drug Saf. 1998;7(6):383–8. doi:10.1002/(SICI)1099-1557(199811/12)7:6<383::AID-PDS377>3.0.CO;2-Q.
28.
Fernández-BañaresFDe SousaMRSalasAEpidemiological risk factors in microscopic colitis: A prospective case-control study. Inflamm Bowel Dis. 2013;19(2):411–7. doi:10.1002/ibd.23009.
29.
Fernandez-BañaresFEsteveMEspinosJCDrug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007;102(2):324–30. doi:10.1111/j.1572-0241.2006.00902.x.
30.
GarbeEAndersohnFBronderEDrug induced immune haemolytic anaemia in the Berlin case-control surveillance study. Br J Haematol. 2011;154(5):644–53. doi:10.1111/j.1365-2141.2011.08784.x.
31.
GarbeEAndersohnFBronderEDrug-induced immune thrombocytopaenia: Results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol. 2012;68(5):821–32. doi:10.1007/s00228-011-1184-3.
32.
GrönhagenCMForedCMLinderMSubacute cutaneous lupus erythematosus and its association with drugs: A population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167(2):296–305. doi:10.1111/j.1365-2133.2012.10969.x.
33.
KeszthelyiDJansenSVSchoutenGAProton pump inhibitor use is associated with an increased risk for microscopic colitis: A case-control study. Aliment Pharmacol Ther. 2010;32(9):1124–8. doi:10.1111/j.1365-2036.2010.04453.x.
34.
KhooTCaugheyGEHillCProton pump inhibitors are not associated with inflammatory myopathies: A case control study. Muscle Nerve. 2018;58(6):855–7. doi:10.1002/mus.26336.
35.
LancashireRJChengKLangmanMJS. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment Pharmacol Ther. 2003;17(7):887–93. doi:10.1046/j.1365-2036.2003.01485.x.
36.
LebwohlBSpechlerSJWangTCUse of proton pump inhibitors and subsequent risk of celiac disease. Dig Liver Dis. 2014;46(1):36–40. doi:10.1016/j.dld.2013.08.128.
37.
LiCDaiYChangYProton pump inhibitors are associated with increased risk of alopecia areata: A nationwide nested case-control study. J Am Acad Dermatol. 2020;83(5):1460–2. doi:10.1016/j.jaad.2020.02.076.
38.
MascleeGMCColomaPMKuipersEJIncreased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015;110(5):749–59. doi:10.1038/ajg.2015.119.
39.
PascuaMFKediaPWeinerMGMicroscopic colitis and medication use. Clinical Medicine Insights Gastroenterology. 2010;2010(3):11–9. doi:10.4137/cgast.s4469.
40.
SundströmABlomgrenKAlfredssonLAcid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis–results from a Swedish case-control study. Pharmacoepidemiol Drug Saf. 2006;15(3):141–9. doi:10.1002/pds.1137.
41.
YuanJZhangCSparksJARegular use of proton pump inhibitor and risk of rheumatoid arthritis in women: A prospective cohort study. Aliment Pharmacol Ther. 2020;52(3):449–58. doi:10.1111/apt.15834.
42.
VerhaeghBPde VriesFMascleeAAKeshavarzianAde BoerASouvereinPCHigh risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):1004–13. doi:10.1111/apt.13583. Epub 2016 March 9. PMID: 26956016.
43.
SchwartzNRMHutflessSHerrintonLJAmsdenLBFevrierHBGieferMProton pump inhibitors, H2 blocker use, and risk of inflammatory bowel disease in children. J Pediatr Pharmacol Ther. 2019;24(6):489–96. doi:10.5863/1551-6776-24.6.489. PMID: 31719810; PMCID: PMC6836698.
44.
ZylberbergHMKambojAKDe CuirNLaneCMKhannaSPardiDSMedication use and microscopic colitis: A multicentre retrospective cohort study. Aliment Pharmacol Ther. 2021;53(11):1209–15. doi:10.1111/apt.13583/10.1111/apt.16363. Epub 2021 April 14. PMID: 33852749.
45.
EggerMDavey SmithGSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. doi:10.1136/bmj.315.7109.629.
46.
ChandeNDrimanDK. Microscopic colitis associated with lansoprazole: Report of two cases and a review of the literature. Scand J Gastroenterol. 2007;42(4):530–3. doi:10.1080/00365520600997296.
47.
LimsuiDPardiDSSmyrkTCObserver variability in the histologic diagnosis of microscopic colitis. Inflamm Bowel Dis. 2009;15(1):35–8. doi:10.1002/ibd.20538.
